6662results about "Macromolecular non-active ingredients" patented technology

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention belongs to the technical field of biomedical materials, and relates to ultrasonic response adhesion integrated hydrogel as well as a preparation method and application thereof, the hydrogel comprises a hydrogel matrix, an interface anchoring agent and a functional load component; the preparation method comprises the following steps: 1, preparing a hydrogel precursor solution, and preparing a hydrogel matrix into a solution; 2, carrying out mold molding or injection crosslinking on the solution prepared in the step 1 to form hydrogel; 3, preparing an interface anchoring agent solution, and dissolving or dispersing an interface anchoring agent in a solvent to prepare the interface anchoring agent solution; the ultrasonic responsive adhesive hydrogel platform provided by the invention can provide an efficient, controllable and universal solution for tissue adhesion, targeted therapy, wearable attachment and the like in a complex microenvironment, and is suitable for a plurality of clinical scenes such as chronic wound management, surgical postoperative closure, infection control, adhesive bioelectronic fixation, soft tissue engineering and the like.

The invention relates to a stable silk fibroin liquid condensation body, gel and a preparation method and application thereof, and belongs to the technical field of silk fibroin. The preparation method comprises the following steps: S1, dissolving silk fibroin in a lithium bromide solution, and then adding trypsin for incubation to obtain an enzyme-digested silk fibroin solution; and S2, performing low-temperature programmed centrifugal treatment including an induction stage, a nucleation stage and a liquid-liquid phase separation stage on the enzyme-digested silk fibroin solution, and cleaning to obtain the stable silk fibroin liquid-state aggregate, the method can reduce aggregate liquid drop aggregation and improve the particle size uniformity of the liquid drops.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The invention discloses a gynecological antibacterial gel containing a carbomer component, and belongs to the technical field of gynecological nursing materials. The gel is prepared from 0.5 to 5 percent of plant extract microcapsules, 0.5 to 3 percent of carbomer, 2 to 10 percent of glycerol, 0.1 to 1.5 percent of triethanol and the balance of purified water. The plant extract microcapsule is prepared by compounding methacrylated silk fibroin and a caffeic acid hyaluronic acid graft, has temperature responsiveness, can improve the adhesive force on the surface of vaginal mucosa, and realizes slow release of the plant extract; the caffeic acid catechol hydroxyl is chelated with silver ions, a nano-silver monodisperse layer is formed on the surface of the microcapsule, and the antibacterial activity is improved. The composite plant extract can inhibit bacteria, repair mucous membranes and maintain the acidic microenvironment of the vagina. When the gel is prepared, the problem that the swelling efficiency of carbomer is low is solved through glycerol pre-grinding, and triethanolamine is added in three times to form a gradient cross-linked network. The problems that traditional gel is unstable in viscosity, poor in mucous membrane adhesiveness and prone to damaging vagina micro-ecology are solved, the antibacterial effect is good, and preservation is stable.

The invention belongs to the technical field of biomedical materials, and particularly relates to adipose-derived mesenchymal stem cell loaded conductive hydrogel and a preparation method and application thereof, the preparation method comprises the following steps: step S1, after hyaluronic acid is subjected to oxidation treatment, dopamine is grafted to oxidized hyaluronic acid, and oxidized hyaluronic acid-dopamine is obtained; step S2, carrying out amination treatment on gelatin to obtain aminated gelatin; s3, mixing the oxidized hyaluronic acid-dopamine with the aminated gelatin, and carrying out Schiff base crosslinking, so as to obtain hydrogel; and step S4, loading the adipose tissue-derived stromal cells by using the hydrogel. Dopamine is grafted on an oxidized hyaluronic acid macromolecular chain through amidation reaction, the hydrophilicity and the electrical property of the macromolecular chain are improved, a catechol structure is provided to provide possibility for iron ion coordination, the tissue adhesion, the injectability, the mechanical property and the electrical conductivity of the hydrogel are improved, and the hydrogel can be applied to the field of biomedical materials. After being applied to a spinal cord injury rat model, the functional recovery can be promoted.

The invention discloses a vitamin K2 composite micro-capsule system with stomach protection and intestine slow release functions and a preparation method and application thereof, the vitamin K2 composite micro-capsule system with stomach protection and intestine slow release functions comprises three layers, namely a core layer, a middle layer and an outer layer from inside to outside in sequence; the core layer is formed by coating vitamin K2 with a zein-lac hydrophobic core, the middle layer is a pea protein-pectin electrostatic compound, and the outer layer is sodium alginate and chitosan double-network gel. The micro-capsule system provided by the invention can be tightly combined in a gastric acid environment after being orally taken, the release of active ingredients in the stomach is reduced, and then the micro-capsule system stays at intestinal mucosa for a long time and slowly releases contents, so that the functions of the micro-capsule system are slowly presented outside, the half-life period is prolonged, and the action effect is improved. Vitamin K2 directly or indirectly participates in and regulates various physiological processes related to health, and plays an important role in the aspects of maintaining bone health, preventing cardiovascular diseases, protecting nerves, improving metabolism and the like.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention belongs to the field of biological materials, and particularly relates to recombinant V-type humanized collagen and application thereof. The invention provides a recombinant V-type humanized collagen, the amino acid sequence of the recombinant V-type humanized collagen comprises (repetitive unit) n, and the repetitive unit comprises a sequence as shown in SEQ ID NO.1; each repeating unit is directly linked and the number n of repeating units is 10. The recombinant V-type humanized collagen can comprehensively resist skin aging.

The invention provides a silk fibroin hydrogel preparation method, which comprises: S1, dissolving degummed silk in a neutral salt solution to obtain a silk fibroin dissolving solution; s2, diluting the silk fibroin dissolving solution prepared in the step S1 with a diluent to obtain a silk fibroin dissolving diluent; s3, carrying out physical cross-linking treatment on the silk fibroin dissolving diluent prepared in the step S2 or regulating the pH value for physical cross-linking or adding a surfactant for physical cross-linking, and incubating to obtain the silk fibroin hydrogel. The silk fibroin hydrogel is simple in preparation process, high in gelling rate, low in loss and high in raw material utilization rate.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention relates to the technical field of biological medicine, in particular to a wound repair material and a preparation method and application thereof.The wound repair material is in a gel shape and comprises hydrogel and platelet-rich plasma, the hydrogel is formed by dynamic crosslinking of collagen and oxidized hyaluronic acid, and the hydrogel physically encapsulates the platelet-rich plasma. The gelatinous wound repair material provides bionic mechanical support through a dynamic cross-linked network, synergistically regulates and controls an inflammation microenvironment and sequential release of PRP growth factors, remarkably promotes angiogenesis and wound healing, is suitable for the clinical treatment fields of diabetic ulcer, chronic difficult-to-heal wounds and the like, and has broad application prospects. The material has the functions of mechanical support, anti-inflammatory regulation and growth factor controlled release.

The invention provides recombinant VIII type humanized collagen and application thereof, and the recombinant VIII type humanized collagen is of a triple helix structure, has good cell adhesion activity, does not generate immunological rejection and anaphylactic reaction when being applied to a human body, is a brand new human body synthetic biological material, and has good application prospects.

Veterinary pharmaceutical compositions for direct systemic introduction, also known as DSI pharmaceutical compositions. One veterinary pharmaceutical composition for direct systemic introduction includes about 10-17 dry mass % bovine gelatin; about 10-17 dry mass % mannitol; about 0-1 dry mass % of a surfactant; and about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction includes combining one or more pharmacologically inactive compounds to form a first solution; using one or more surfactants to form a second solution; adding an active pharmaceutical ingredient to the second solution to form a first mixture; adding the first solution to the first mixture to form a pre-formulation; freezing the pre-formulation; and lyophilizing the pre-formulation.

The invention relates to hydrogel loaded with oxygen self-producing nanoparticles as well as a preparation method and application of the hydrogel. The preparation method comprises the following steps: 1, taking cross-linked methacrylamide silk fibroin and hyaluronic acid modified by arginine-glycine-aspartic acid peptide as base materials, and loading self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG, and the self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG are prepared by coating Cu-EGCG on calcium peroxide nano particles modified by PVP modified polyvinylpyrrolidone. The hydrogel can improve energy metabolism and regulate immune environment through dual mechanisms, realizes efficient promotion of myocardial repair, and provides a new strategy and thought for tissue regeneration and functional recovery after myocardial infarction.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The purpose of the present invention is to provide a lipid composition capable of delivering a nucleic acid such as RNA to a hematopoietic stem / progenitor cell or a mesenchymal stem cell, and a method for delivering a therapeutic agent to a cell using the lipid composition. The present invention provides a lipid composition comprising (A) a therapeutic agent and (B) a lipid nanoparticle conjugated to a targeting molecule wherein the lipid nanoparticle comprises an ionizable lipid and the targeting molecule specifically binds to a marker of hematopoietic stem / progenitor cells or mesenchymal stem cells.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

According to some embodiments, a patch for organ and / or tissue application is provided which comprises a biocompatible polymeric material having an auxetic architecture and further matching a stiffness ratio and / or Poisson's ratio of an organ or tissue to which the patch is applied. According to some further embodiments, biocompatible patches and methods of making the same are provided comprising providing a layer of hydrogel and forming an auxetic architecture by selectively crosslinking areas of the hydrogel via exposure to light, wherein the auxetic architecture is selected to match a stiffness ratio and Poisson's ratio of an organ to which the biocompatible patch is applied.

The invention belongs to the technical field of probiotic preparations, and particularly relates to bifidobacterium longum subsp. Longum and application thereof in resisting helicobacter pylori. The bifidobacterium longum subsp. Longum provided by the invention has a good inhibition effect on helicobacter pylori. Furthermore, the bifidobacterium longum subsp. Longum is effectively embedded through enzyme cross-linking and ionic cross-linking by adopting the bifidobacterium longum subsp. Longum, so that not only can the embedding rate of the strain be improved, but also the survival rate of the strain can be remarkably improved in a digestion environment, and the efficient planting of the strain is realized; particularly, the effect of resisting helicobacter pylori infection can be obviously improved. Therefore, the invention has important practical significance on prevention and treatment of helicobacter pylori infection, and can also provide a technical basis for application of anti-helicobacter pylori functional products in the future.

The invention relates to the field of biomedical materials, in particular to composite hydrogel as well as a preparation method and application thereof. The composite hydrogel prepared by the invention realizes step-by-step release and time sequence regulation of a polypeptide drug through the combined action of Gel-PBA and GelMA: the anti-inflammatory peptide (Ac2-26) is quickly released under the conditions of high ROS and low pH, so that inflammation and pyroptosis are reduced; osteogenic peptide (OGP) is continuously and slowly released, and osteogenic differentiation is promoted. The step-by-step release mechanism of the anti-inflammatory peptide and the osteogenic peptide can realize accurate drug release, and is helpful for synergistically regulating inflammation and promoting bone regeneration. The composite hydrogel is used as a biological medicine material, can realize timely anti-inflammatory effect and long-term osteogenesis in a complex pathological environment such as diabetic periodontitis, and has a good application prospect.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention belongs to the technical field of food processing, and particularly relates to a curcumin-loaded protein-polysaccharide nanoparticle delivery system, a preparation method thereof and application of the curcumin-loaded protein-polysaccharide nanoparticle delivery system in neuroprotection. The preparation method comprises the following steps: mixing and dissolving sodium caseinate with one of glucan and pectin, hydrating at 0-4 DEG C for 12-24 hours, and performing ultrasonic and microwave treatment to obtain a pretreatment solution; adjusting the pH value, and heating the pretreatment solution to obtain covalent grafted particles; the protein-polysaccharide covalent grafted particles obtained in the second step are encapsulated with curcumin through a pH shift method, and the protein-polysaccharide-curcumin nanoparticles are obtained. The invention provides a method for carrying out Maillard reaction on sodium caseinate-polysaccharide under the assistance of ultrasound and microwaves, reaction parameters are optimized, and a preparation method of an efficient and stable curcumin delivery system and application of the curcumin delivery system in neuroprotection are constructed.

The invention provides a halite-containing probiotic preparation for improving gastrointestinal environment and a preparation method, the halite-containing probiotic preparation comprises the following components in parts by weight: 60-70 parts of a probiotic composition, the probiotic composition comprises lactobacillus casei Zhang, animal bifidobacterium subsp. Lactis V9, lactobacillus plantarum P-01, animal bifidobacterium subsp. Lactis B-01 and casei paracasei LC-11, the weight ratio is 3: 2: 2: 1: 1. 1.2 to 3.5 parts of nanoscale refined halite; 10 to 15 parts of a microcapsule embedding material; 0.6 to 1.2 parts of an antioxidant system; 15 to 30 parts of auxiliary materials; the probiotic preparation disclosed by the invention has the characteristics of obvious strain combination advantage, nano-scale halite protection and synergism, accurate release of a multi-layer microcapsule structure, synergistic effect of an antioxidant system and the like, the survival rate of probiotics, gastrointestinal tract tolerance and intestinal colonization capacity are remarkably improved, and a new technical scheme is provided for improving gastrointestinal health.